Immunogenicity of the DNA/Protein Combined Vaccine against COVID-19
During the COVID-19 pandemic, the development of prophylactic vaccines, including those based on new platforms, became highly relevant. One such platform is the creation of vaccines combining DNA and protein components in one construct. For the creation of DNA vaccine, we chose the full-length spike protein (S) of the SARS-CoV-2 virus and used the recombinant receptor-binding domain (RBD) of the S protein produced in CHO-K1 cells as a protein component. The immunogenicity of the developed combined vaccine and its individual components was compared and the contribution of each component to the induction of the immune response was analyzed. The combined DNA/protein vaccine possesses the advantages of both underlying approaches and is capable of inducing both humoral (similar to subunit vaccines) and cellular (similar to DNA vaccines) immunity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Bulletin of experimental biology and medicine - 174(2022), 2 vom: Dez., Seite 246-249 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borgoyakova, M. B. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10517-023-05682-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049030736 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049030736 | ||
| 003 | DE-627 | ||
| 005 | 20230519071400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230111s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10517-023-05682-9 |2 doi | |
| 035 | |a (DE-627)SPR049030736 | ||
| 035 | |a (SPR)s10517-023-05682-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borgoyakova, M. B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity of the DNA/Protein Combined Vaccine against COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a During the COVID-19 pandemic, the development of prophylactic vaccines, including those based on new platforms, became highly relevant. One such platform is the creation of vaccines combining DNA and protein components in one construct. For the creation of DNA vaccine, we chose the full-length spike protein (S) of the SARS-CoV-2 virus and used the recombinant receptor-binding domain (RBD) of the S protein produced in CHO-K1 cells as a protein component. The immunogenicity of the developed combined vaccine and its individual components was compared and the contribution of each component to the induction of the immune response was analyzed. The combined DNA/protein vaccine possesses the advantages of both underlying approaches and is capable of inducing both humoral (similar to subunit vaccines) and cellular (similar to DNA vaccines) immunity. | ||
| 700 | 1 | |a Karpenko, L. I. |4 aut | |
| 700 | 1 | |a Merkulyeva, I. A. |4 aut | |
| 700 | 1 | |a Shcherbakov, D. N. |4 aut | |
| 700 | 1 | |a Rudometov, A. P. |4 aut | |
| 700 | 1 | |a Starostina, E. V. |4 aut | |
| 700 | 1 | |a Shanshin, D. V. |4 aut | |
| 700 | 1 | |a Isaeva, A. A. |4 aut | |
| 700 | 1 | |a Nesmeyanova, V. S. |4 aut | |
| 700 | 1 | |a Volkova, N. V. |4 aut | |
| 700 | 1 | |a Belenkaya, S. V. |4 aut | |
| 700 | 1 | |a Volosnikova, E. A. |4 aut | |
| 700 | 1 | |a Zadorozhny, A. M. |4 aut | |
| 700 | 1 | |a Orlova, L. A. |4 aut | |
| 700 | 1 | |a Zaykovskaya, A. V. |4 aut | |
| 700 | 1 | |a Pyankov, O. V. |4 aut | |
| 700 | 1 | |a Bazhan, S. I. |4 aut | |
| 700 | 1 | |a Ilyichev, A. A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin of experimental biology and medicine |d Dordrecht [u.a.] : Springer Science + Business Media B. V., 1956 |g 174(2022), 2 vom: Dez., Seite 246-249 |w (DE-627)SPR010703306 |w (DE-600)2037110-X |x 1573-8221 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2022 |g number:2 |g month:12 |g pages:246-249 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10517-023-05682-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2022 |e 2 |c 12 |h 246-249 | ||